BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/25/2025 1:11:36 AM | Browse: 388 | Download: 919
Publication Name World Journal of Stem Cells
Manuscript ID 111978
Country Saudi Arabia
ISSN 1948-0210 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cell & Tissue Engineering
Manuscript Type Meta-Analysis
Article Title Living bio-drug therapies using mesenchymal stem cells and exosomes for mechanically ventilated patients with acute respiratory distress syndrome: A systematic review and meta-analysis
Manuscript Source Invited Manuscript
All Author List Moaz Safwan, Mariam Safwan Bourgleh, Abdulsalam Al-Ruqi, Omran Shrebaty, Faisal Almujaydil, Basel AlOthaim, Nasser AlRashidi and Khawaja Husnain Haider
ORCID
Author(s) ORCID Number
Khawaja Husnain Haider http://orcid.org/0000-0002-7907-4808
Funding Agency and Grant Number
Corresponding Author Khawaja Husnain Haider, PhD, Professor, Department of Basic Sciences, Sulaiman Al Rajhi University, PO Box 777, Al Bukairiyah 51941, AlQaseem, Saudi Arabia. khhaider@gmail.com
Key Words Acute respiratory distress syndrome; COVID-19; Exosomes; Living bio-drugs; Mesenchymal stem cells; Meta-analysis; Network stem cells
Core Tip Mesenchymal stem cells, as a living bio-drug, are being considered a potential treatment for coronavirus disease 2019-induced acute respiratory distress syndrome due to their immunomodulatory and reparative properties. Our systematic review and meta-analysis, involving 16 randomized controlled trials (n = 1027 acute respiratory distress syndrome patients), is the first study to directly compare the therapeutic benefits of mesenchymal stem cell-based and their derivative exosome-based therapeutic approaches. Although we did not find significant differences in their safety profiles and efficacy, the exosome-based treatment ranked higher in terms of therapeutic benefits in a network meta-analysis, offering practical and logistical advantages.
Publish Date 2025-10-25 01:11
Citation

Safwan M, Bourgleh MS, Al-Ruqi A, Shrebaty O, Almujaydil F, AlOthaim B, AlRashidi N, Haider KH. Living bio-drug therapies using mesenchymal stem cells and exosomes for mechanically ventilated patients with acute respiratory distress syndrome: A systematic review and meta-analysis. World J Stem Cells 2025; 17(10): 111978

URL https://www.wjgnet.com/1948-0210/full/v17/i10/111978.htm
DOI https://dx.doi.org/10.4252/wjsc.v17.i10.111978
Full Article (PDF) WJSC-17-111978-with-cover.pdf